Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
1(25%)
Results Posted
200%(2 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_2
2
50%
Ph not_applicable
1
25%
Ph phase_1
1
25%

Phase Distribution

1

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(1)
Terminated(2)

Detailed Status

Completed1
Recruiting1
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (25.0%)
Phase 22 (50.0%)
N/A1 (25.0%)

Trials by Status

completed125%
recruiting125%
terminated125%
withdrawn125%

Recent Activity

1 active trials
Showing 4 of 4
recruitingphase_2

The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes

NCT06976619
completedphase_1

Use of a GLP-1R Agonist to Treat Opioid Use Disorder

NCT04199728
terminatedphase_2

Efficacy of Liraglutide Therapy in Patients With IPAA

NCT04763564
withdrawnnot_applicable

Liraglutide for Low-responders After Bariatric Surgery

NCT04643301

Clinical Trials (4)

Showing 4 of 4 trials
NCT06976619Phase 2

The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes

Recruiting
NCT04199728Phase 1

Use of a GLP-1R Agonist to Treat Opioid Use Disorder

Completed
NCT04763564Phase 2

Efficacy of Liraglutide Therapy in Patients With IPAA

Terminated
NCT04643301Not Applicable

Liraglutide for Low-responders After Bariatric Surgery

Withdrawn

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4